We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 6 for:    "glycogen storage disease type III" OR "Glycogen Storage Disease Type III"

Prospective Follow-up of Patients With Glycogen Storage Disease Type III (PRO GSDIII)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2012 by Institut de Myologie, France.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01563705
First Posted: March 27, 2012
Last Update Posted: December 20, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Institut de Myologie, France
  Purpose
The aim of this study is to improve knowledge of natural history and methods of monitoring the evolution of Glycogen storage disease type III regarding the muscle and to study the prospective approach of large series of patients, and using the same protocol for the follow up of the children and adults.

Condition Intervention
Neuromuscular Disorders Procedure: Different motor function tests Procedure: Manual dexterity assessment

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Prospective Follow-up of Patients With Glycogen Storage Disease Type III

Resource links provided by NLM:


Further study details as provided by Institut de Myologie, France:

Primary Outcome Measures:
  • Knee flexion and extension strength [ Time Frame: at baseline ]
  • Knee flexion and extension strength [ Time Frame: 2 years after baseline ]
  • Knee flexion and extension strength [ Time Frame: 4 years after baseline ]
  • Time to perform each motor function test [ Time Frame: at baseline ]
  • Time to perform each motor function test [ Time Frame: 2 years after baseline ]
  • Time to perform each motor function test [ Time Frame: 4 years after baseline ]
  • Gait speed measured during the 6 minutes walk test [ Time Frame: at baseline ]
  • Gait speed measured during the 6 minutes walk test [ Time Frame: 2 years after baseline ]
  • Gait speed measured during the 6 minutes walk test [ Time Frame: 4 years after baseline ]

Secondary Outcome Measures:
  • Accelerometric variables measured for the 6 minutes walk test [ Time Frame: At baseline ]
  • Accelerometric variables measured for the 6 minutes walk test [ Time Frame: 2 years after baseline ]
  • Accelerometric variables measured for the 6 minutes walk test [ Time Frame: 4 years after baseline ]
  • NMR variables measured during each specific NMR sequence [ Time Frame: at baseline ]
  • NMR variables measured during each specific NMR sequence [ Time Frame: 2 years after baseline ]
  • NMR variables measured during each specific NMR sequence [ Time Frame: 4 years after baseline ]

Estimated Enrollment: 30
Study Start Date: February 2011
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Different motor function tests
    Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
    Procedure: Manual dexterity assessment
    Purdue pegboard test
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   10 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with a debranching enzyme deficiency confirmed by enzymatic analysis (debranching enzyme deficiency).
  • Written consent
  • Age: at least 10 years
  • Affiliated with a social security system

Exclusion Criteria:

  • Pregnant and lactating women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01563705


Contacts
Contact: Pascal Laforet, MD 00 331 42 16 37 75 pascal.laforet@psl.aphp.fr
Contact: Pierre Carlier, MD, PhD p.carlier@institut-myologie.org

Locations
France
Institut de Myologie Recruiting
Paris, France
Contact: Pascal Laforet, MD    00 331 42 16 37 75    pascal.laforet@psl.aphp.fr   
Contact: Pierre Carlier, MD, PhD       p.carlier@institut-myologie.org   
Sponsors and Collaborators
Institut de Myologie, France
  More Information

Responsible Party: Institut de Myologie, France
ClinicalTrials.gov Identifier: NCT01563705     History of Changes
Other Study ID Numbers: 2010-A00615-34
First Submitted: March 21, 2012
First Posted: March 27, 2012
Last Update Posted: December 20, 2012
Last Verified: December 2012

Keywords provided by Institut de Myologie, France:
Neuromuscular Disorders
GSD III
glycogen storage disease

Additional relevant MeSH terms:
Glycogen Storage Disease
Neuromuscular Diseases
Glycogen Storage Disease Type III
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Nervous System Diseases